Wellnex Life Limited

Board/Management Information • Sep 19, 2025

National Storage Mechanism | Additional information

RNS Number : 0374A

Wellnex Life Limited

19 September 2025

ASX/AIM Announcement                                                                                  19 September 2025

Wellnex Life Limited (ASX/AIM: WNX)

Appointment of Non-executive Chair

Wellnex Life Limited ("Wellnex" or the "Company") (ASX/AIM: WNX) is pleased to announce that, further to the Company's announcement on 9 September 2025 and the conclusion of customary due diligence by the Company's Nominated Advisor on AIM, Ash Vesali has been appointed to the Board as Non-Executive Chairman with immediate effect.

Additional Information :

Save for the information set out above and below, there are no further disclosures to be made in accordance with Rule 17 and Schedule Two, paragraph (g), of the AIM Rules in respect of the appointment of Ash Vesali.

Arash Vesali (aged 49) does not currently hold, or has held in the last 5 years, any directorships or partnerships.

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

For further information, please contact:

Wellnex Life Limited (ASX:WNX)                                  Reach Markets

Zack Bozinovski                                                            T: 1300 805 795

Chief Executive Officer & Managing Director                  E: [email protected]

P: +61 3 8399 9419

E: [email protected]

UK Investors

Strand Hanson (Financial & Nominated Advisor)     

James Harris / Richard Johnson                                     Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker)                                            [email protected]

Sebastian Wykeham     

S.P. Angel Corporate Finance LLP (Joint Broker)                        Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

To learn more, please visit: www.WellnexLife.com.au/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAEKLBFEKLLBBZ